Patent · US Active

Antigen binding molecules targeting SARS-CoV-2

US11981725B2 · kind B2 · utility

0Cited by

9References

25Claims

0Family size

Assignee

Flagship Pioneering Innovations VI, LLC · US

Inventors

Gevorg Grigoryan · Arlington, US
John Ingraham · Falls Church, US
Cheuk Lun Leung · Cambridge, US
Ross Steven Federman · Milton Village, US
Robin Jeffrey Green · Cambridge, US
Alexis Hiram Ramos · Cambridge, US
Jenhan Tao · Cambridge, US

Key dates

Filing date	Jan 6, 2023
Grant date	May 14, 2024
Priority date	—
Expiry date	Jan 6, 2043

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention provides, in various embodiments, polypeptides that specifically bind to Spike glycoprotein of severe acute respiratory syndrome coronavirus (e.g., SARS-CoV-2-Spike). The invention also provides, in various embodiments, fusion proteins comprising one or more of the polypeptides, polynucleotides encoding the polypeptides, vectors and host cells suitable for expressing the polypeptides, and methods for treating viral infections (e.g., COVID-19).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.